From Seeking Alpha:
China Biotech in Review: The Business of China Life Science
August 16, 2009
Most of the stories emanating from the world of China life science had to do with the business side of the segment: an IPO, a possible takeover, new capital and earnings – lots of earnings. In addition, there were cross-border deals that will introduce new products to China and China products to the rest of the world, plus new product approvals and China-France collaborative research...
...Shenzhen Mellow Hope Pharm Industrial Co., a subsidiary of Hard to Treat Diseases [Pink Sheets: HTDS], has reached an agreement to be the sole international distributor of a Recombinant Hepatitis B vaccine manufactured by North China Pharmaceutical Group (see story). NCPC is a large state-owned pharmaceutical company, with a specialty in vaccines.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment